(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 9.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.42%.
Catalyst Pharmaceuticals's revenue in 2026 is $588,989,000.On average, 9 Wall Street analysts forecast CPRX's revenue for 2026 to be $78,548,860,950, with the lowest CPRX revenue forecast at $74,328,259,519, and the highest CPRX revenue forecast at $82,033,055,360. On average, 9 Wall Street analysts forecast CPRX's revenue for 2027 to be $86,805,656,747, with the lowest CPRX revenue forecast at $75,737,569,140, and the highest CPRX revenue forecast at $93,339,284,541.
In 2028, CPRX is forecast to generate $94,124,541,115 in revenue, with the lowest revenue forecast at $82,737,710,171 and the highest revenue forecast at $106,008,416,267.